BRCA1 and BRCA2: 1994 and beyond

[1]  A. Manoharan.  Fanconi anaemia , 2006, British journal of haematology.

[2]  T. Rebbeck,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers , 2004 .

[3]  A. Jakubowska,et al.  A high proportion of founder BRCA1 mutations in Polish breast cancer families , 2004, International journal of cancer.

[4]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[6]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[7]  E. Solomon,et al.  BRCA1 : BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. , 2004, Human molecular genetics.

[8]  A. Venkitaraman.  Tracing the network connecting brca and fanconi anaemia proteins , 2004, Nature Reviews Cancer.

[9]  Susan L Neuhausen,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Chenevix-Trench,et al.  Germ‐line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen‐responsive proteins and the predominance of progesterone receptor A , 2004, Genes, chromosomes & cancer.

[11]  J. Houwing-Duistermaat,et al.  Are ATM Mutations 7271T→G and IVS10-6T→G Really High-Risk Breast Cancer-Susceptibility Alleles? , 2004, Cancer Research.

[12]  D. Papadopoulo,et al.  Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations , 2004, Oncogene.

[13]  W. Foulkes.  BRCA1 functions as a breast stem cell regulator , 2004, Journal of Medical Genetics.

[14]  J. Klijn,et al.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. , 2003, Cancer research.

[15]  Luke Hughes-Davies,et al.  EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.

[16]  A. Howell,et al.  Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? , 2003, Breast Cancer Research.

[17]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[18]  Kenneth Offit,et al.  Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. , 2003, Journal of the National Cancer Institute.

[19]  L. Bégin,et al.  Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma , 2003, Cancer.

[20]  M. Monden,et al.  Mutational analysis of BARD1 in familial breast cancer patients in Japan. , 2003, Cancer letters.

[21]  J. D. den Dunnen,et al.  An alternative to FISH: detecting deletion and duplication carriers within 24 hours , 2003, Journal of medical genetics.

[22]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[23]  William Rostène,et al.  Antiestrogens are pro‐apoptotic in normal human breast epithelial cells , 2003, International journal of cancer.

[24]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Monteiro,et al.  BRCA1: the enigma of tissue-specific tumor development. , 2003, Trends in genetics : TIG.

[26]  S. Pinder,et al.  Prognostic significance of BRCA1 expression in sporadic breast carcinomas , 2003, The Journal of pathology.

[27]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[28]  C. Boland,et al.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.

[29]  C. Hudis,et al.  Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations , 2003, Cancer.

[30]  M. Ringnér,et al.  Molecular classification of familial non-BRCA1/BRCA2 breast cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Bégin,et al.  Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma , 2003, Cancer.

[32]  P. Gregersen,et al.  Frequency of CHEK2*1100delC in New York breast cancer cases and controls , 2003, BMC Medical Genetics.

[33]  M. Jasin.  Homologous repair of DNA damage and tumorigenesis:the BRCA connection , 2002, Oncogene.

[34]  Marcel J T Reinders,et al.  Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. , 2002, Cancer research.

[35]  S. Narod,et al.  Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2 , 2002, Human mutation.

[36]  I. Andrulis,et al.  HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry , 2002, Cancer.

[37]  Martin Eisenacher,et al.  Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.

[38]  M. Klinger,et al.  Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families , 2002, Journal of medical genetics.

[39]  S. Narod,et al.  A low frequency of non‐founder BRCA1 mutations in Ashkenazi Jewish breast–ovarian cancer families , 2002, Human mutation.

[40]  A. Howell,et al.  Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy , 2002, International journal of cancer.

[41]  Z. Aziz,et al.  Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. , 2002, American journal of human genetics.

[42]  J. Ford,et al.  BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.

[43]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[44]  P. Chappuis,et al.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.

[45]  G. Parmigiani,et al.  Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families , 2002, Journal of medical genetics.

[46]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[47]  R. Barkardottir,et al.  The effect of a single BRCA2 mutation on cancer in Iceland , 2002, Journal of medical genetics.

[48]  A. Whittemore,et al.  Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.

[49]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.

[50]  Hermann Herbst,et al.  Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept , 2002, Laboratory Investigation.

[51]  J. Peto.  Breast cancer susceptibility-A new look at an old model. , 2002, Cancer cell.

[52]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[53]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[54]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[55]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[56]  S. Elledge,et al.  The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. , 2002, Cancer cell.

[57]  E. Sensi,et al.  Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations , 2002, Genes, chromosomes & cancer.

[58]  D. Papadopoulo,et al.  A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining , 2002, Oncogene.

[59]  J. Sambrook,et al.  Dominant negative ATM mutations in breast cancer families. , 2002, Journal of the National Cancer Institute.

[60]  S. Narod.  Modifiers of risk of hereditary breast and ovarian cancer , 2002, Nature Reviews Cancer.

[61]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[62]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[63]  T. Dörk,et al.  Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Seal,et al.  Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  E. Ostrander,et al.  Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations inBRCA1 , 2001, Journal of medical genetics.

[66]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[67]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[68]  D. Evans,et al.  Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res., 60: 390-394, 2000. , 2001, Cancer research.

[69]  D. Cameron,et al.  The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. , 2001, European journal of cancer.

[70]  P. Kyyrönen,et al.  Survival of breast cancer patients in BRCA1, BRCA2, and non‐BRCA1/2 breast cancer families: A relative survival analysis from Finland , 2001, International journal of cancer.

[71]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[72]  M. Jasin,et al.  Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. , 2001, Cancer research.

[73]  T. Ohta,et al.  The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.

[74]  A. Aurias,et al.  Color bar coding the BRCA1 gene on combed DNA: A useful strategy for detecting large gene rearrangements , 2001, Genes, chromosomes & cancer.

[75]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[76]  D. Sgroi,et al.  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.

[77]  D. Birnbaum,et al.  Assessing the risk of BRCA1‐associated breast cancer using individual morphological criteria , 2001, Histopathology.

[78]  S. Narod.  Roads to breast cancer. , 2001, The New England journal of medicine.

[79]  B. Friedenson.  Roads to breast cancer. , 2001, The New England journal of medicine.

[80]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[81]  G. Giles,et al.  After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. , 2001, American journal of human genetics.

[82]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[83]  Jing Chen,et al.  Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.

[84]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[85]  D. Haber.  Roads leading to breast cancer. , 2000, The New England journal of medicine.

[86]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[87]  H. Piwnica-Worms,et al.  Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. , 2000, Cancer research.

[88]  M. Perricaudet,et al.  BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. , 2000, Cancer research.

[89]  William Rostène,et al.  Hormonal regulation of apoptosis in breast cells and tissues , 2000, Steroids.

[90]  S. Elledge,et al.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Seal,et al.  Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22 , 2000, Oncogene.

[92]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[93]  E. Gillanders,et al.  Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[94]  C. Deng,et al.  Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[95]  G. Lenoir,et al.  Regional methylation of the 5’ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[96]  Alexander Kinev,et al.  BRCA1 Is Associated with a Human SWI/SNF-Related Complex Linking Chromatin Remodeling to Breast Cancer , 2000, Cell.

[97]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[98]  B. Weber,et al.  An Alu‐mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10 , 2000, Genes, chromosomes & cancer.

[99]  P. Chappuis,et al.  Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. , 2000, Seminars in surgical oncology.

[100]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[101]  A. Monteiro,et al.  Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. , 2000, Cancer research.

[102]  S. Elledge,et al.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. , 2000, Genes & development.

[103]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[104]  D. Fishman,et al.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. , 2000, American journal of human genetics.

[105]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[106]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[107]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[108]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[109]  W. Vogel,et al.  Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. , 2000, Cancer research.

[110]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[111]  M. Perricaudet,et al.  Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2 , 1999, Oncogene.

[112]  A. Tward,et al.  Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. , 1999, Molecular genetics and metabolism.

[113]  D. Livingston,et al.  Genetic analysis of BRCA1 function in a defined tumor cell line. , 1999, Molecular cell.

[114]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[115]  G E Tomlinson,et al.  BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.

[116]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[117]  W. Foulkes,et al.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.

[118]  S. Carr,et al.  Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.

[119]  I. Ellis,et al.  BRCA1 expression levels predict distant metastasis of sporadic breast cancers , 1999, International journal of cancer.

[120]  R. Yarden,et al.  BRCA1 interacts with components of the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[121]  D Lowe,et al.  Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Journal of the National Cancer Institute.

[122]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[123]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[124]  D. Stoppa-Lyonnet,et al.  Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. , 1999, Cancer research.

[125]  G. Lenoir,et al.  Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region , 1998, Oncogene.

[126]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[127]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[128]  B. Modan,et al.  Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. , 1998, Journal of the National Cancer Institute.

[129]  T. Sørlie,et al.  Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases , 1998, Breast Cancer Research and Treatment.

[130]  N. Zeps,et al.  Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. , 1998, Differentiation; research in biological diversity.

[131]  J. Eyfjörd,et al.  BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. , 1998, Cancer research.

[132]  D. Easton,et al.  ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. , 1998, American journal of human genetics.

[133]  A. Ashworth,et al.  Functions of the BRCA1 and BRCA2 genes. , 1998, Current opinion in genetics & development.

[134]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[135]  P. Bartel,et al.  RAD51 Interacts with the Evolutionarily Conserved BRC Motifs in the Human Breast Cancer Susceptibility Gene brca2 * , 1997, The Journal of Biological Chemistry.

[136]  T. Mak,et al.  Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation , 1997, Nature Genetics.

[137]  F. Alt,et al.  RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[138]  F. Collins,et al.  Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[139]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[140]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[141]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[142]  K. Isselbacher,et al.  Heterozygous ATM mutations do not contribute to early onset of breast cancer , 1997, Nature Genetics.

[143]  G. Lenoir,et al.  A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. , 1997, Cancer research.

[144]  P. Schlag,et al.  Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families , 1997, Oncogene.

[145]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[146]  J. Mornon,et al.  From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair , 1997, FEBS letters.

[147]  A. Godwin,et al.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.

[148]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[149]  D. B. Berman,et al.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.

[150]  Kenneth Offit,et al.  The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% , 1996, Nature Genetics.

[151]  J. Rossant,et al.  The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.

[152]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[153]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[154]  F. Collins.  BRCA1--lots of mutations, lots of dilemmas. , 1996, The New England journal of medicine.

[155]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[156]  D. Easton,et al.  Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[157]  J. Chang-Claude,et al.  High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families , 1995 .

[158]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[159]  A. Jeffreys,et al.  A somatic BRCA1 mutation in an ovarian tumour , 1995, Nature Genetics.

[160]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.

[161]  J. Rommens,et al.  Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families , 1994, Nature Genetics.

[162]  Francis S. Collins,et al.  Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer , 1994, Nature Genetics.

[163]  D. Birnbaum,et al.  Evidence for a third breast-cancer susceptibility gene , 1994, The Lancet.

[164]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[165]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[166]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[167]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[168]  M. King,et al.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q , 1994, Nature Genetics.

[169]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[170]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[171]  M. Skolnick,et al.  Inheritance of proliferative breast disease in breast cancer kindreds. , 1990, Science.

[172]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[173]  A. Brøgger,et al.  Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes. , 1988, Mutation research.

[174]  M. Swift,et al.  CANCER AND CARDIAC DEATHS IN OBLIGATORY ATAXIA-TELANGIECTASIA HETEROZYGOTES , 1983, The Lancet.

[175]  I. Andrulis,et al.  Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. , 2004, Annals of epidemiology.

[176]  B. Ponder,et al.  Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. , 2003, American journal of human genetics.

[177]  Daniel J Schaid,et al.  Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers , 2003, Cancer.

[178]  L. Kiemeney,et al.  High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[180]  Anne,et al.  BREAST CANCER AFTER PROPHYLACTIC BILATERAL MASTECTOMY IN WOMEN WITH A BRCA 1 OR BRCA 2 MUTATION , 2001 .

[181]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[182]  J. Varley,et al.  Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families , 2001 .

[183]  F. Alt,et al.  RAB 22 and RAB 163 y mouse BRCA 2 : Proteins that specifically interact with the RAD 51 protein , 1997 .

[184]  F. Collins,et al.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.

[185]  J. Klijn,et al.  Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.

[186]  D. Easton.  Cancer risks in A-T heterozygotes. , 1994, International journal of radiation biology.

[187]  H T Lynch,et al.  Hereditary breast cancer. , 1991, Annals of medicine.

[188]  T. Halazonetis,et al.  Chk 2 / hCds 1 functions as a DNA damage checkpoint in G 1 by stabilizing p 53 , 2022 .

[189]  J. Ford,et al.  BRCA 1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2022 .